Patient sex, diagnosis, and array platform used
| Patient no. . | Sex . | Diagnosis . | Primary diagnosis . | Array pPlatform . |
|---|---|---|---|---|
| 1 | Female | HL, NS | Yes | Affymetrix |
| 2 | Male | HL, MC | Yes | Affymetrix |
| 3 | Male | HL, NS | Yes | Affymetrix |
| 4 | Male | HL, not specified | No | Affymetrix |
| 5 | Male | HL, NS | Yes | Illumina |
| 6 | Female | HL, NS | Yes | Illumina |
| 7 | Male | HL, NS | Yes | Illumina |
| 8 | Female | HL, NS | Yes | Illumina |
| 9 | Female | HL, NS | No | Illumina |
| 10 | Male | Monocytoid B-cell reaction | Yes | Affymetrix |
| 11 | Female | Reactive changes | Yes | Affymetrix |
| 12 | Male | Lymphadenitis | Yes | Affymetrix |
| 13 | Female | Lymphadenitis | Yes | Affymetrix |
| 14 | Male | Reactive changes | Yes | Affymetrix |
| 15 | Female | Reactive changes | Yes | Illumina |
| 16 | Male | Lymphadenitis | Yes | Illumina |
| 17 | Female | Reactive changes | Yes | Illumina |
| 18 | Male | Reactive changes | Yes | Illumina |
| 19 | Male | FL, grade II | Yes | Affymetrix |
| 20 | Male | FL, grade I | No | Affymetrix |
| 21 | Male | FL, grade I | Yes | Affymetrix |
| 22 | Male | FL, grade I | Yes | Illumina |
| 23 | Male | FL, grade I | Yes | Illumina |
| 24 | Female | FL, grade II | Yes | Illumina |
| 25 | Male | FL, grade I | Yes | Illumina |
| 26 | Male | FL, grade II | Yes | Illumina |
| 27 | Female | FL, grade I | Yes | Illumina |
| 28 | Female | HL, MC; FL in premedical history | No | Illumina |
| 29 | Male | B-NHL | Yes | Illumina |
| 30 | Male | Reactive changes, proven LP-HD in different LN | No | Illumina |
| Patient no. . | Sex . | Diagnosis . | Primary diagnosis . | Array pPlatform . |
|---|---|---|---|---|
| 1 | Female | HL, NS | Yes | Affymetrix |
| 2 | Male | HL, MC | Yes | Affymetrix |
| 3 | Male | HL, NS | Yes | Affymetrix |
| 4 | Male | HL, not specified | No | Affymetrix |
| 5 | Male | HL, NS | Yes | Illumina |
| 6 | Female | HL, NS | Yes | Illumina |
| 7 | Male | HL, NS | Yes | Illumina |
| 8 | Female | HL, NS | Yes | Illumina |
| 9 | Female | HL, NS | No | Illumina |
| 10 | Male | Monocytoid B-cell reaction | Yes | Affymetrix |
| 11 | Female | Reactive changes | Yes | Affymetrix |
| 12 | Male | Lymphadenitis | Yes | Affymetrix |
| 13 | Female | Lymphadenitis | Yes | Affymetrix |
| 14 | Male | Reactive changes | Yes | Affymetrix |
| 15 | Female | Reactive changes | Yes | Illumina |
| 16 | Male | Lymphadenitis | Yes | Illumina |
| 17 | Female | Reactive changes | Yes | Illumina |
| 18 | Male | Reactive changes | Yes | Illumina |
| 19 | Male | FL, grade II | Yes | Affymetrix |
| 20 | Male | FL, grade I | No | Affymetrix |
| 21 | Male | FL, grade I | Yes | Affymetrix |
| 22 | Male | FL, grade I | Yes | Illumina |
| 23 | Male | FL, grade I | Yes | Illumina |
| 24 | Female | FL, grade II | Yes | Illumina |
| 25 | Male | FL, grade I | Yes | Illumina |
| 26 | Male | FL, grade II | Yes | Illumina |
| 27 | Female | FL, grade I | Yes | Illumina |
| 28 | Female | HL, MC; FL in premedical history | No | Illumina |
| 29 | Male | B-NHL | Yes | Illumina |
| 30 | Male | Reactive changes, proven LP-HD in different LN | No | Illumina |
NS indicates nodular sclerosis; MC, mixed cellularity; LP-HD, lymphocyte-predominant Hodgkin disease; and LN, lymph node.